Dendreon shares jump ahead of Provenge data

NEW YORK, April 3 (Reuters) - Shares of Dendreon Corp (DNDN.O) jumped 38 percent on Friday as investors looked ahead to long-awaited data on the company's experimental Provenge vaccine to treat advanced prostate cancer.

A spokeswoman for the U.S. biotechnology company, Katherine Stueland, said she knew of no clear reason for the stock gains. But she noted that the American Urological Association on Friday had reserved a time slot at one of its upcoming scientific meetings for Provenge researchers to present findings from a late-stage trial of the product.

[ Read Article ]